Kornimate/medical-research-clean huggingface dataset:
rapid diagnostic supporting antimicrobial stewardship in patients with pneumonia

Conditions: Lower Respiratory Tract Infections

Summary: the purpose of this study is to determine whether or not the filmarray penumonia panel adds value to patient care.


Eligibility criteria:
inclusion criteria: - subjects who have the following samples collected and submitted for culture as part of routine clinical practice: expectorated sputum, induced sputum, tracheal secretions, bronchoalveolar lavage. exclusion criteria: * subjects who do not have mn research authorization on file * rejected sputum culture (i.e., due to low quality) * positive respiratory cultures within prior 7 days * deceased at time of sample randomization * any subject affected by global data protection regulation (gdpr) * previous enrollment in the study. * outpatient status
a study of nm21-1480 in adult patients with advanced solid tumors

Conditions: Advanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Fallopian Tube Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer

Summary: this is a first-in-human, open-label, multi-center, phase 1/2, dose-escalation study with expansion cohorts to evaluate nm21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.


Eligibility criteria:
inclusion criteria: part a * patients with any previously treated solid tumor-type other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma that is advanced, or recurrent and progressing since last anti-tumor therapy, and for which no alternative, standard therapy exists. * prior chemotherapy, radiation therapy or immunotherapy must have been completed at least 4 weeks prior to the administration of the first dose of study drug, and patient has recovered part b: * patients with non-small cell lung cancer (nsclc) or other protocol specified solid tumors with locally advanced or metastatic, non-resectable disease, which has progressed despite treatment with first-line standard of-care treatment, or first- and second-line treatment, dependent on expansion cohort. * prior therapy must have been completed 2-4 weeks prior to the administration of the first dose of study drug as specified per protocol according to type of prior therapy exclusion criteria: * patient previously had known immediate or delayed hypersensitivity reaction or idiosyncrasy to the excipients * part a: treatment with any pd-1, or cytotoxic t-lymphocyte associated protein (ctla)-4 directed antibody, or with any other immunotherapy within 4 weeks prior to initiation of the study drug. * part a: use of other biological investigational drugs (drugs not marketed for any indication), including use of investigational drugs targeting cd137/4-1bb within at least 5 half-lives (or within 8 weeks, whatever is longer) prior to the administration of the first dose of study drug. * part b: as defined per protocol for each expansion cohort, has not been treated with specified first/second-line standard-of-care therapies biological drugs (marketed or investigational) for treatment of the current cancer, or has not adequately recovered from aes that occurred with prior therapy. * patient has an active autoimmune disease or a documented history of autoimmune disease.

Keywords: carcinoma neoplasms
fibre supplements for pre-diabetes - an assessment oral fibre supplements on pre-diabetes outcome measures

Conditions: Pre-diabetes

Summary: this trial will investigate whether a powdered fibre mix helps maintain healthy blood glucose levels in participants with pre-diabetes, where high blood sugar is a risk of diabetes.

pre-diabetes is characterised by high blood glucose levels, high plasma cholesterol, low-density lipoprotein (ldl) and high-density lipoprotein (hdl). dietary fibre consumption has been hypothesised to improve these metabolic parameters through the viscous properties, and the production of short-chain fatty acids (scfa) in the intestine.

Eligibility criteria:
inclusion criteria: * able and willing to provide informed consent * have a body mass index (bmi) of at least 25 kg/m2 * men or post menopausal\* women aged 18-70 * identified as pre-diabetic (hba1c 6.0% (42 mmol/mol) to 6.4% (47 mmol/ mol)) within the previous 12 months * baseline hba1c result within the range 5.8% (40 mmol/mol) - 6.5% (48 mmol/mol) * willing to complete in clinic blood tests and a participant trial survey * have access to a smartphone or a computer exclusion criteria: * receiving medication to treat type 1 or type 2 diabetes in the previous 6 months * have a body mass index (bmi) \ 45 kg/m2 * loss of more than 5% body weight in last 3 months * current participation in weight loss program or planned in the next 16 weeks * steroid use (except for over the counter nsaid's, topical steroids and inhalers) * severe hepatic diseases (including chronic persistent hepatitis, liver cirrhosis or the co-occurrence of positive hepatitis b virus surface antigen and abnormal hepatic transaminase (serum concentrations of alanine transaminase or aspartate transaminase \>2.5× the upper normal limit)) * continuous antibiotic use for \>3 days within 4 weeks prior to enrolment * continuous use of weight-loss drug for within 3 months of study entry
bronkow program and lumbar stabilization exercises in chronic non specific low back pain

Conditions: Chronic Low-back Pain; Non Specific Low Back Pain

Summary: the aim of this study is to compare the effects of brunkow exercise program and lumbar stabilization exercises on pain, range of motion and disability in patients with chronic non- specific low back pain

the majority of research studies have primarily focused on lumbar stabilization exercises used as a standard treatment with mobilization. to the best of our knowledge it has shown that lumbar stabilization exercises alone are less efficient than lumbar stabilization exercises in strengthening muscular strength and decreasing pain in female patients with persistent low back pain than lumbar stabilization exercises combined with pain neuroscience education. however, more extensive research on a range of educational and activity programs was required. stabilization exercises with other modalities, manual techniques, mobilizations, or exercise therapy have been practiced in the treatment of chronic non specific low back pain were found effective individually, but there was a lack of comprehensive studies including randomized clinical trials directly comparing the brunkow exercises program with stabilization exercises in patients with chronic non- specific low back pain. this study investigates and adds up an effective and evolutionary treatment protocol in the world of physical therapy for the management of chronic non-specific low back pain rather than other conventional therapy providing to the patients with chronic low back pain now a days.

Eligibility criteria:
inclusion criteria: * age 20 to 45 years * both male and female * low back pain \> 6 months * nprs\>3 * the symptoms of pain are lessened or disappeared after bed rest, while pain symptoms are aggravated after bending over, sitting for a long time, or standing for a long time. exclusion criteria: * pelvic bone fracture * pregnancy * pelvic implants * lumbosacral disc herniation * sacroiliac joint inflammation * lumbar spine fracture * inflammatory bowel disease * malignancy * ankylosing spondylitis

Keywords: brunkow exercise disability non-specific low back pain pain range of motion
acute presentation and management of abdominal tuberculosis: a ten-year experience at a tertiary care center in pakistan

Conditions: Tuberculosis; Abdomen

Summary: a prospective interventional study was conducted in services instituton of medical sciences all patients who underwent emergency laparotomy from 2008-2018 due to abdominal tuberculosis. data were analyzed using spss version 21


Eligibility criteria:
inclusion criteria: * both sexes and age between years and 90 years * patients presenting with acute abdomen and who underwent exploratory laparotomy * patients who diagnosis confirmed on biopsy (caseating granulomas) exclusion criteria: * peritoneal tuberculosis * other causes of acute abdomen (typhoid perforation) * patients diagnosed with abdominal tuberculosis and on conservative management
an expanded access ind for the treatment of chronic inflammatory demyelinating polyneuropathy (cidp)

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Summary: this is an individual patient expanded access ind to evaluate the safety and preliminary efficacy of autologous hb-admscs for treating a single patient chronic inflammatory demyelinating polyneuropathy, cidp. the expanded access program will include a screening period of up to 28 days, a 44-week treatment period, a safety follow-up at 50, and a 52-week end-of-study visit.

an informed consent form will be given to the participant, who will sign before any procedures. the informed consent form will include information about this expanded access and all the aspects considered during this process. the participant is required to complete the subsequent visits after they have given their informed consent. * visit 1 - screening during this period, the principal investigator will determine whether the screened participant is eligible and whether the next visit can be scheduled. once the principal investigator has evaluated the eligibility (up to 28 days), the patient will be scheduled for the first infusion. * visit 2 - infusion 1 (baseline): this visit will be a starting point for comparing participant's data. during this visit, the patient will receive the 1st investigational product via intravenous infusion, with rigorous monitoring of vital signs for a total of 2 hours. * visit 3 to 12 - during these visits, the patient will receive intravenous infusions of hb- admscs while her vital signs are precisely monitored for a total of 2 hours. * follow-up phone call - during this safety follow-up phone call, the principal investigator will evaluate the safety of the investigational product by conducting several assessments described in the schedule of assessments table. * end of study - at the end of the expanded access program visit, the principal investigator will conduct various evaluations to determine the patient's physical condition and assess whether there have been any safety events resulting from the participation in the expanded access program.

Eligibility criteria:
* inclusion criteria * patient diagnosed with chronic inflammatory demyelinating polyneuropathy, cidp, with documented medical records. * patient must have banked his stem cells at hope biosciences llc. * exclusion criteria * the patient has any active infection requiring medications. * the patient has any suicidal ideation during the screening visit or at any point during the study.
rifampicin resistance in s. aureus during and after treatment for latent tuberculosis

Conditions: Latent Tuberculosis; Staphylococcus Aureus

Summary: two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. the invistigators will study the risk of acquisition of rifampicin resistance in commensal staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. finally, household contacts to persons with rifampicin-resistant s. aureus will be examined to investigate whether onward transmission of rifampicin-resistant s. aureus occurs within households.

the use of rifampicin for treatment of latent tuberculosis has gained popularity due to a shorter treatment course compared with isoniazide (4 versus 6-9 months) since this can lead to a higher proportion of treatment completion. an estimated 25% of the global population is latently infected with tuberculosis. hence, a shift towards rifampicin instead of isoniazide, which has a more narrow antibacterial spectrum, could have a large impact on the prevalence of rifampicin resistance among commensal bacteria with pathogenic potential, such as staphylococcus aureus (s.aureus). the investigators will investigate the risk of acquisition of rifampicin resistance in commensal s.aureus during out-patient treatment for latent tuberculosis using 4 months rifampicin versus 6-9 months isoniazide at skåne university hospital in malmö, sweden. swabs will be obtained from the nose, throat, groin and possible wounds for culture and resistance testing before, during and after cessation of treatment for latent tuberculosis. whole genome sequencing will be used to analyze accumulation of mutations over time and to determine if it is the primarily detected s.aureus that develop resistance or if the individual is colonized by new, rifampicin-resistant s.aureus over the course of treatment. household contacts to persons with rifampicin-resistant s.aureus will be examined to investigate onward spread of bacteria within a household.

Eligibility criteria:
inclusion criteria: * diagnosed with latent tuberculosis * prescribed either 4 months rifampicin or 6-9 months isoniazide * informed consent exclusion criteria: * none

Keywords: rifampicin isoniazide staphylococcus aureus latent tuberculosis drug resistance, microbial
effects of pdt and bioceramic filling on periapical healing and postoperative pain after endodontic retreatment

Conditions: Apical Periodontitis

Summary: the purpose is to investigate influence of bioceramic filling of the root canal and photodynamic therapy on periapical healing and development of postoperative pain after endodontic retreatment. patients are divided into two main groups and each of the group is divided into two subgroups. main groups are patients receiving photodynamic therapy and patients receiving passive ultrasonic irrigation. each of the main group is divided by the root canal filling material on the ah+ group and bioroot group.

clinical trial will be conducted in dental clinic zagreb. patients will be chosen for this randomized prospective trials from the everyday patients referred by general dentist for endodontic retreatment. in the research will be included only patients with symptoms of chronic apical periodontitis and previous endodontic treatment. it includes teeth sensitive to palpation, percussion or visible sinus tract or swelling and asymptomatic inadequate endodontic filling. patients that are immunocompromised, pregnant women, teeth with pocket depth bigger then 3mm, teeth with signs of vertical root fracture, teeth that are impossible to restore are excluded from research. every patient will be assigned to one group and one subgroup using "wheeldecide" programme. patients will not be aware what group or subgroup they are assigned. endodontic retreatment will be conducted by one specialist in endodontics. therapy is single visit retreatment.

Eligibility criteria:
inclusion criteria: * patients with symptoms of periapical disease after endodontic treatment, * teeth sensitive to percussion and palpation, * teeth with present sinus tract and * asymptomatic teeth with radiologically inadequate root canal filling. exclusion criteria: * immunocompromised patients, * pregnancy, * teeth with signs of vertical root fracture, * teeth that can't be restored, * antibiotic usage within last month, * teeth with acute apical abscess

Keywords: biomaterials irrigation protocol pariapical healing
coated mongolian aneurysm treatment study 1

Conditions: Intracranial Aneurysm; Aneurysm; Vascular Diseases

Summary: the purpose of this study is to assess safety and effectiveness of the p64 mw hpc or p48 mw hpc flow modulation device under dual antiplatelet medication.

title: observational registry with p64 mw hpc and p48 mw hpc in unruptured anterior circulation aneurysms under dual antiplatelet medication. purpose: to assess safety and effectiveness of p64 mw hpc or p48 mw hpc under dual antiplatelet medication in consecutive patients with unruptured anterior circulation aneurysms. follow-up intervals: independent follow-ups (after 3 to 6 months and after 12 months and after 24 months) according to site specific standard.

Eligibility criteria:
inclusion criteria: * at least one unruptured sidewall aneurysm in the anterior circulation * no implant (e.g., stent) in the target vessel segment * age \>18 years and \<80 years * not pregnant and in women of childbearing age, on oral contraception for two years following the procedure * no participation in another trial * no concomitant disease limiting the life expectancy to \<2 years * no allergy to non-ionic contrast medium or to asa and p2y12 receptor antagonists * no other neurovascular disorder in the same vascular territory requiring treatment in the foreseeable future * ability and willingness to comply with the medication requirements within the study, * ability to understand the goal and risks of this study. exclusion criteria: * intracranial aneurysm considered not suitable for fd using p64 mw hpc or p48 mw hpc. * aneurysm previously treated with a device in the parent vessel (e.g., stent, flow diverter). * another intracranial procedure scheduled for the following 6 months. * age \ 80 years. * pregnancy possible or confirmed. patient not able or willing to arrange contraception for 12 months after treatment. * patient not able or willing to adhere to the study protocol. * patient not able or willing to undergo the scheduled follow-up examinations.

Keywords: p64 mw hpc p48 mw hpc flow diverter hpc dual antiplatelet therapy outcome occlusion stroke
foxiga korea local phase 4 study

Conditions: Diabetes Mellitus, Type 2

Summary: to evaluate the effect of dapagliflozin on body composition in korean t2dm subjects.12-month, randomised, open-label, parallel-group, multi-centre phase iv study.

this is a 52 weeks, randomized, open-label, parallel-group, multi-centres phase iv study. participants will be randomized 1:1 to receive dapagliflozin 10 mg qd or glimepiride 1\~2 mgqd in an open-label manner for 12 months as add-on to metformin 1000 mg. parallel group study design was chosen. in order maintain the practicality of the phase iv study, open label design of study drug delivery was chosen. the reading of the dxa scans will be conducted by one expert in blinded manner. glimepiride is the most frequently used sus in korea and therefore this was chosen as comparator.dapagliflozin treatment will be associated with reduction of total body fm, bw, abdominal vat and sat volume compared with glimepiride.

Eligibility criteria:
inclusion criteria: 1. adults with t2dm (male or female, ≥ 19 and ≤ 75 yrs) 2. patients in insufficient glycemic control (hba1c \> 7.5% and \< 9.5% in recent 4 weeks) 3. patients with an unchanged dose of metformin (≥ 1,000 mg/day) for \> 8 weeks prior to randomization 4. written informed consent 5. wocbp must take precautions to avoid pregnancy throughout the study and for 4 weeks after intake of the last dose. * wocbp must have a negative urine pregnancy test at screening visit wocbp include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal. * wocbp must be willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator. exclusion criteria: 1. type 1 diabetes or history of diabetic ketoacidosis 2. pregnant or breast-feeding patients 3. egfr \< 60 ml/min/1.73 m2 (mdrd) on visit 1. 4. indication of active liver disease (ast/alt/total bilirubin \> 3 x upper limits of normal) on visit 1. 5. acute coronary syndrome, stroke or tia within 3 months prior to randomization 6. bariatric surgery within 2 years; treatment of anti-obesity drugs 3 months prior to randomization; any treatment leading to unstable body weight. (unstable body weight is considered reliable in the judgment of the investigator.) 7. history of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time 8. history of any other malignancy within 5 years (with the exception of successfully treated non-melanoma skin cancers) 9. history of alcohol or drug abuse judged by physician within 3 months prior to randomization 10. concomitant participation in any other clinical study.

Keywords: dm
resting-state functional connectivity as a predictor of tdcs effects in adolescents with autism spectrum disorder

Conditions: Autism Spectrum Disorder (ASD); Transcranial Direct Current Stimulation (tDCS); Electroencephalography

Summary: background: transcranial direct current stimulation (tdcs) is a form of non-invasive brain stimulation that has aroused increased interests in the past decade. not only that it is transient with little side-effects, and can be well-tolerated by children, it is also affordable and readily accessible, making it an appealing treatment option for autism spectrum disorder (asd). objective: (1) to evaluate the therapeutic effects of tdcs on improving cognitive function in patients with asd, (2) to better understand the neural mechanisms underlying the neuromodulation effects of tdcs in patients with asd, and (3) to determine whether resting-state functional connectivity measures can predict the therapeutic effects of active tdcs in individuals with asd. methods: to assess the therapeutic effects and neural mechanisms of tdcs, 90 adolescents with asd (age 12-22 years) will receive three stimulation conditions: cathodal tdcs of the left dlpfc, anodal tdcs of the left dlpfc and sham-tdcs with at least a week apart each time. during the active tdcs or sham-tdcs condition, the participants will be administered a computerized test battery (cambridge neuropsychological test automated battery, cantab®) to evaluate their cognitive function. eeg before and after the tdcs to evaluate the tdcs-induced alteration in their neural activity and functional connectivity. hypothesis: drawing together the different evidence linking asd with cortical hyper-excitability and disordered neural connectivity, as reviewed previously, we hypothesize that, relative to a sham-tdcs condition, active cathodal (inhibitory) and anodal (excitatory) tdcs over the left dlprc will induce stimulation-linked facilitation of learning and resultant improvement of cognitive functioning in patients with asd. in addition to the therapeutic effects of tdcs, enhanced neural connectivity, as indexed by altered level eeg theta coherence in patients with asd, will mediate the beneficial effects of tdcs, relative to sham tdcs, on improvements in cognitive function. moreover, resting-state functional connectivity will moderate the beneficial effects of active tdcs on cognitive function, relative to sham tdcs, such that participants with greater pre-treatment resting state functional connectively will evidence greater/less response to tdcs, relative to participants receiving sham tdcs.


Eligibility criteria:
inclusion criteria: * being 12-22 years old * diagnosed with asd given by registered psychiatrists or clinical psychologists according to the diagnostic and statistical manual of mental disorders-5th edition (dsm-5) criteria of asd * able to communicate in chinese exclusion criteria: * without a confirmed diagnosis from the clinical psychologist * history of other neurological and psychiatric disorders and head trauma * on psychiatric medication